DNTH
Price
$23.67
Change
-$0.03 (-0.13%)
Updated
Feb 21 closing price
Capitalization
700.56M
PRME
Price
$2.96
Change
-$0.17 (-5.43%)
Updated
Feb 21 closing price
Capitalization
388.24M
11 days until earnings call
Ad is loading...

DNTH vs PRME

Header iconDNTH vs PRME Comparison
Open Charts DNTH vs PRMEBanner chart's image
Dianthus Therapeutics
Price$23.67
Change-$0.03 (-0.13%)
Volume$304.05K
Capitalization700.56M
Prime Medicine
Price$2.96
Change-$0.17 (-5.43%)
Volume$805.56K
Capitalization388.24M
DNTH vs PRME Comparison Chart
Loading...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNTH vs. PRME commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNTH is a Hold and PRME is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (DNTH: $24.22 vs. PRME: $2.99)
Brand notoriety: DNTH and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNTH: 115% vs. PRME: 155%
Market capitalization -- DNTH: $700.56M vs. PRME: $388.24M
DNTH [@Biotechnology] is valued at $700.56M. PRME’s [@Biotechnology] market capitalization is $388.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNTH’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • DNTH’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, DNTH is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNTH’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 5 bullish TA indicator(s).

  • DNTH’s TA Score: 5 bullish, 3 bearish.
  • PRME’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both DNTH and PRME are a good buy in the short-term.

Price Growth

DNTH (@Biotechnology) experienced а +3.68% price change this week, while PRME (@Biotechnology) price change was +31.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.27%. For the same industry, the average monthly price growth was +3.99%, and the average quarterly price growth was +2.35%.

Reported Earning Dates

DNTH is expected to report earnings on Nov 09, 2023.

PRME is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (+4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNTH($701M) has a higher market cap than PRME($388M). DNTH YTD gains are higher at: 11.101 vs. PRME (2.397). DNTH has higher annual earnings (EBITDA): -82.47M vs. PRME (-207.13M). DNTH has more cash in the bank: 281M vs. PRME (176M). DNTH has less debt than PRME: DNTH (311K) vs PRME (41.2M). DNTH has higher revenues than PRME: DNTH (5.37M) vs PRME (800K).
DNTHPRMEDNTH / PRME
Capitalization701M388M181%
EBITDA-82.47M-207.13M40%
Gain YTD11.1012.397463%
P/E Ratio3.28N/A-
Revenue5.37M800K671%
Total Cash281M176M160%
Total Debt311K41.2M1%
FUNDAMENTALS RATINGS
DNTH vs PRME: Fundamental Ratings
DNTH
PRME
OUTLOOK RATING
1..100
1070
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
71
Overvalued
PROFIT vs RISK RATING
1..100
43100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
4564
P/E GROWTH RATING
1..100
65100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNTH's Valuation (57) in the null industry is in the same range as PRME (71). This means that DNTH’s stock grew similarly to PRME’s over the last 12 months.

DNTH's Profit vs Risk Rating (43) in the null industry is somewhat better than the same rating for PRME (100). This means that DNTH’s stock grew somewhat faster than PRME’s over the last 12 months.

DNTH's SMR Rating (95) in the null industry is in the same range as PRME (100). This means that DNTH’s stock grew similarly to PRME’s over the last 12 months.

DNTH's Price Growth Rating (45) in the null industry is in the same range as PRME (64). This means that DNTH’s stock grew similarly to PRME’s over the last 12 months.

DNTH's P/E Growth Rating (65) in the null industry is somewhat better than the same rating for PRME (100). This means that DNTH’s stock grew somewhat faster than PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNTHPRME
RSI
ODDS (%)
N/A
Bullish Trend 6 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
78%
Momentum
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 6 days ago
83%
MACD
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 6 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 6 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 6 days ago
73%
Advances
ODDS (%)
Bullish Trend 10 days ago
79%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 28 days ago
87%
Bearish Trend 13 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
86%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 6 days ago
90%
View a ticker or compare two or three
Ad is loading...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with ANNX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then ANNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
-1.10%
ANNX - DNTH
41%
Loosely correlated
-12.05%
SLDB - DNTH
41%
Loosely correlated
+31.51%
TRDA - DNTH
40%
Loosely correlated
-2.60%
PRME - DNTH
39%
Loosely correlated
+5.28%
RNA - DNTH
39%
Loosely correlated
-0.96%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+5.28%
CRSP - PRME
64%
Loosely correlated
+5.03%
BEAM - PRME
59%
Loosely correlated
+3.36%
NTLA - PRME
57%
Loosely correlated
+7.76%
ALLO - PRME
54%
Loosely correlated
+39.22%
RXRX - PRME
53%
Loosely correlated
+1.04%
More